With Novartis Korea nearing reimbursement listing for its 2 ultra high-priced drugs, how the two drugs will progress is receiving attention.

The two Novartis drugs that have continuously raised issues since its domestic approval are ‘Kymriah (tisagenlecleucel) and Zolgensma (onasemnogene abeparvovec-xioi). Among the two drugs, Kymirah was first listed for reimbursement in April, and the drug pricing negotiations with the National Health Insurance Service for Zolgensma were also completed recently.

When Zolgensma passes deliberation by the Health Insurance Policy Deliberation Committee (HIPDC), the drug will also be applied the prior approval system like Kymriah. If approved, it will be th